Globus Medical (GMED) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Globus Medical (GMED) PT Raised to $65 at Needham & Company
August 2, 2018 8:15 AM EDTNeedham & Company raised its price target on Globus Medical (NYSE: GMED) to $65.00 (from $58.00) while maintaining a Buy rating following 2Q earnings report. Revenue was $173M vs. consensus of $168M and non-GAAP EPS was $0.44 vs. consensus of $0.35.
For 2018, GMED raised its revenue... More
